中国实用儿科杂志

中国实用儿科杂志 ›› 2023, Vol. 38 ›› Issue (9): 689-695.DOI: 10.19538/j.ek2023090608

• 专题笔谈 • 上一篇    下一篇

生物制剂在儿童中重度特应性皮炎治疗中的研究进展

  

  1. 1.上海交通大学医学院附属新华医院皮肤科，上海  200092；2.上海交通大学医学院皮肤病研究所，上海  200092；3.复旦大学附属儿科医院皮肤科，上海  201102 注：赵安琪和潘超兰对本文有同等贡献，均为共同第一作者
  • 出版日期:2023-09-06 发布日期:2023-09-22
  • 通讯作者: 李明，电子信箱：mingli@fudan.edu.cn

Research progress in the use of biological agents in the treatment of moderate-to-severe pediatric atopic derma-titis 

  1. *Department of Dermatology， Xinhua Hospital， Shanghai Jiaotong University School of Medicine， Shanghai　200092， China HAO An-qi and PAN Chao-lan are the first anthors who contributed equally to the article
  • Online:2023-09-06 Published:2023-09-22

摘要： 特应性皮炎（atopic dermatitis，AD）是一种慢性、复发性、瘙痒性、炎症性皮肤病，严重影响患者的生存质量。传统治疗如外用糖皮质激素、钙调磷酸酶抑制剂等在中重度患者的治疗中具有局限性。随着对疾病发病机制的深入理解，生物制剂展示出巨大的应用前景。该文总结了有关生物制剂治疗儿童AD患者的临床研究，为临床医生提供相关前沿信息。

关键词: 儿童, 特应性皮炎, 生物制剂

Abstract: Atopic dermatitis （AD） is a chronic， relapsing， pruritic， and inflammatory skin disease that significantly affects patients' quality of life. Traditional treatment options， such as topical corticosteroids and topical calcineurin inhibitors， have limitations in the treatment of moderate-to-severe AD. With an improved understanding of the pathoge-nesis of AD， biological agents have emerged as a promising treatment option. This article aims to provide clinicians with current and relevant information on the use of biological agents in the treatment of pediatric AD by summarizing the clinlcal trials. 

Key words: child, atopic dermatitis, biological agents